Results 11 to 20 of about 461 (125)

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review [PDF]

Diseases
Obesity is a growing global health challenge, necessitating effective treatment options beyond lifestyle interventions. This narrative review explores established and emerging pharmacotherapies for weight management, including parenteral agents like ...
Abdullah Al Lawati, Ayman Alhabsi, Rhieya Rahul, Maria-Luisa Savino, Hamed Alwahaibi, Srijit Das, Hanan Al Lawati   +6 more
doaj   +6 more sources

Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials [PDF]

BMJ Open
Background Incretin-based drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly used in the management of type 2 diabetes mellitus and obesity ...
Matthew Meng Yang Lee, Janus C Jakobsen, Jens Dahlgaard Hove, Mohammed El-Sheikh, Johannes Grand, Christina Dam Bjerregaard Sillassen, Frederik Dencker Wisborg, Carsten Dirksen   +7 more
doaj   +5 more sources

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies [PDF]

Metabolism Open
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Ioannis G. Lempesis, Maria Dalamaga
doaj   +2 more sources

Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes [PDF]

Metabolism Open
Introduction: Amylin-pathway therapies represent a novel therapeutic class for obesity and type 2 diabetes, however head-to-head comparative data and long-term outcome predictions remain limited.
Faisal A. Al-Harbi, Ahmed K. Alsaif, Atheer G. Almutairi, Hussam J. Alshehri, Elan A. Aleidan, Ghaida S. Alabdulaaly, Mashael E. Alanazi, Ahmed Y. Azzam   +7 more
doaj   +2 more sources

Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes

Clinical Research and Clinical Trials, 2023
Cagrilintide is a long-acting amylin receptor agonist that lowers body weight and controls hyperglycemia through various actions. In a phase 2 trial of obese subjects, cagrilintide used in different subcutaneous doses once weekly was associated with a mean weight loss of 6-10.8% after 26 weeks, compared with 9.0% with the glucagon-like 1 receptor (GLP ...
exaly   +2 more sources

Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis

Journal of Clinical Question
Introduction: Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and amylin analogues, have emerged as promising treatments for obesity.
Yange Meng, Ting Jin, Luping Ren, Michelle L. Thompson, Yue Wang   +4 more
doaj   +2 more sources

Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis

Journal of Clinical Question
Introduction: Type 2 diabetes mellitus (T2DM) is commonly associated with obesity and increased cardiometabolic risk, highlighting the need for therapies that optimize both glycemic control and weight management.
Ting Jin, Yange Meng, Luping Ren, Yue Wang   +3 more
doaj   +2 more sources

Characterization of 0839 – A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide

Life Sciences
Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for mouse and rat in vivo and in vitro studies of amylin analogues such as cagrilintide.
Kirsten Raun
exaly   +3 more sources

Incretin-based therapies for the treatment of obesity-related diseases [PDF]

npj Metabolic Health and Disease
Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and ...
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Sebastio Perrini, Francesco Giorgino   +4 more
doaj   +2 more sources

Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors

Acta Pharmacologica Sinica
The global obesity epidemic and its associated metabolic disorders urgently require more effective therapeutic interventions, particularly multi-pathway targeting therapies. Cagrilintide (Cagri), functioning as a dual amylin receptor (AMYRs) and calcitonin receptor (CTR) agonist (DACRA), demonstrates significant efficacy in obesity treatment, although ...
H Eric Xu, Li-Hua Zhao, Xu H Eric
exaly   +3 more sources